Ascendis Pharma A/S (ASND) Stock Price & Analysis
Ascendis Pharma A/S (ASND) closed at USD 242.99 on Thursday, October 22, 2026, up 1.71% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 238.9; the Oct 22, 2026 session ranged USD 236.87–243.87 on volume of 539,163 shares. Market capitalization is $15.99B, with a 52-week range of USD 188.07–282.15 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ASND.md
Key facts (ASND)
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $5.5M; 3 not under a Rule 10b5-1 plan ($5.5M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 5 Form 4 filings, $777K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.76 on a 1–5 scale) (21 analysts), mean target USD 307.57 (range 261.99–349.56).
- Total return with dividends: 1Y +20.9% vs S&P 500 +14.9%; 5Y +68.0% vs S&P 500 +80.3%.
Insider sales (SEC Form 4, open-market, last ~7 months) (ASND)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff Mads | SVP & PAO | 3,000 | $811K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-02 | Holtug Lars | Director | 236 | $62K | 5.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-11 | Jensen Flemming Steen | See Remarks | 19,460 | $4.6M | 100% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (ASND)
5 purchases, $777K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-14 | Bienaime Jean Jacques | Director | 2,000 | $493K | 246.33 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-02 | Smith Scott Thomas | EVP & Chief Financial Officer | 100 | $22K | 219 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-29 | Bienaime Jean Jacques | Director | 500 | $112K | 223.12 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-29 | Smith Scott Thomas | EVP & Chief Financial Officer | 250 | $56K | 223.32 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-26 | Bienaime Jean Jacques | Director | 400 | $95K | 237.8 | Too little history (no open-market trades in 2023–2025) |
Analysts (ASND)
Consensus Buy (mean 1.76 on a 1–5 scale), 21 analysts; mean target USD 307.57 (low 261.99, high 349.56).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-25 | Cantor Fitzgerald | Reiterated | Overweight | $300 |
| 2026-09-15 | Raymond James | Downgrade | Strong Buy → Outperform | $287 |
| 2026-09-02 | Oppenheimer | Target raised | Outperform | $304 → $312 |
| 2026-09-01 | Morgan Stanley | Target lowered | Overweight | $275 → $273 |
| 2026-09-01 | Wedbush | Reiterated | Outperform | $327 |
| 2026-08-31 | B of A Securities | Target lowered | Buy | $306 → $304 |
| 2026-08-31 | Jefferies | Target lowered | Buy | $333 → $330 |
| 2026-08-31 | Stifel | Target lowered | Buy | $328 → $326 |
| 2026-08-31 | HC Wainwright & Co. | Target lowered | Buy | $345 → $344 |
| 2026-08-27 | HC Wainwright & Co. | Initiated | Buy | $345 |
| 2026-08-19 | BMO Capital | Initiated | Outperform | $319 |
| 2026-08-14 | TD Cowen | Target raised | Buy | $325 → $341 |
Total return (dividends reinvested) (ASND)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +20.9% | +68.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +21.0% | +10.9% |
| Volatility (annualized) | 38.9% | 47.8% |
| Max drawdown | -19.7% (Jul 2026→Oct 2026) | -56.5% (Nov 2021→Apr 2023) |
ASND suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | WuXi | “We may also rely on other foreign contract research organizations ("CROs"), and contract manufacturing organizations ("CMOs"), such as WuXi Biologics.” |
| Supplier | Bachem | “Our growth hormone parent drug as well as our TransCon hGH drug substance are supplied by both Fujifilm Diosynth Biotechnologies UK Limited ("Fujifilm"), and Lonza Ltd. Our PTH as well as our TransCon PTH drug substance is supplied by Bachem, Switzerland, pursuant to our agreement with Bachem.” |
| Supplier | Fujifilm Diosynth Biotechnologies UK | “Our growth hormone parent drug as well as our TransCon hGH drug substance are supplied by both Fujifilm Diosynth Biotechnologies UK Limited ("Fujifilm"), and Lonza Ltd. Our PTH as well as our TransCon PTH drug substance is supplied by Bachem, Switzerland, pursuant to our agreement with Bachem.” |
| Supplier | Lonza | “Our growth hormone parent drug as well as our TransCon hGH drug substance are supplied by both Fujifilm Diosynth Biotechnologies UK Limited ("Fujifilm"), and Lonza Ltd. Our PTH as well as our TransCon PTH drug substance is supplied by Bachem, Switzerland, pursuant to our agreement with Bachem.” |
| Partner | Novo Nordisk (NVO) | “For example, in November 2024, we entered into a research and development collaboration and license agreement with Novo Nordisk A/S ("Novo Nordisk"), pursuant to which we granted Novo Nordisk an exclusive worldwide license to our TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive license in cardiovascular…” |
| Partner | NOF | “As another example, in November 2023, we announced that we entered into an exclusive license agreement with Teijin Limited, ("Teijin"), to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP for certain endocrinology rare diseases in Japan.” |
| Partner | Teijin | “As another example, in November 2023, we announced that we entered into an exclusive license agreement with Teijin Limited, ("Teijin"), to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP for certain endocrinology rare diseases in Japan.” |
| Partner | Eyconis | “The timing and amount of any milestone and royalty payments we may receive under agreements with collaboration partners and the value of any equity we own in our collaboration partners (such as the equity we own in VISEN and Eyconis) will depend on, among other things, the efforts, allocation of resources, and successful development and commercialization of our products or product candidates by our collaboration p…” |
| Partner | Pfizer (PFE) | “Pfizer (in collaboration with OPKO Health Inc.) has received regulatory approval of once-weekly somatrogon (brand name NGENLA) in more than 40 countries for pediatric GHD.” |
| Partner | OPKO HEALTH, INC. (OPK) | “Pfizer (in collaboration with OPKO Health Inc.) has received regulatory approval of once-weekly somatrogon (brand name NGENLA) in more than 40 countries for pediatric GHD.” |
| Partner | CARBOGEN AMCIS | “The intermediates of our proprietary TransCon linkers are made by CARBOGEN AMCIS AG under an agreement with CARBOGEN AMCIS AG and accompanying purchase orders.” |
| Partner | Artisan Partners Asset Management Inc. (APAM) | “Consists of an aggregate of 3,225,885 ADSs beneficially owned, or that may be deemed to be beneficially owned, by Artisan Partners Limited Partnership ("APLP"), Artisan Investments GP LLC ("Artisan Investments"), Artisan Partners Holdings LP ("Artisan Holdings") and Artisan Partners Asset Management Inc. ("APAM") as reported by Amendment No. 6 to Schedule 13G filed on February 3, 2026.” |
| Competitor | Eli Lilly (LLY) | “In addition, TransCon IL-2 b/g may face competition from drug candidates in development for platinum resistant ovarian cancer, including Astra Zeneca, Corcept, Daiichi Sankyo, Eli Lilly, Genelux, Genmab, and Merck.” |
| Competitor | Merck (MRK) | “In addition, TransCon IL-2 b/g may face competition from drug candidates in development for platinum resistant ovarian cancer, including Astra Zeneca, Corcept, Daiichi Sankyo, Eli Lilly, Genelux, Genmab, and Merck.” |
Quoted from the company's 20-F filed Feb 11, 2026.
ASND analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.94 | $1.32 | -28.6% | $367.3M | 3 |
| Next quarter (ends Dec 2026) | $1.15 | $1.59 | -27.6% | $415.4M | 3 |
| Current fiscal year (ends Dec 2026) | $12.79 | $11.73 | +9.1% | $1.38B | 5 |
| Next fiscal year (ends Dec 2027) | $9.62 | $9.29 | +3.6% | $2.02B | 5 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 242.99 |
|---|---|
| Change | ▲ 1.71% (up) |
| Previous Close | USD 238.9 |
| Open | USD 239.38 |
| Day Range | USD 236.87 – 243.87 |
| 52-Week Range | USD 188.07 – 282.15 |
| Volume | 539,163 shares |
| Market Cap | $15.99B |
| Exchange | NMS |
Technical Analysis (ASND)
Nexqual's technical model rates ASND "NEUTRAL" based on 4 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.71 (neutral) |
| vs SMA50 | Above (USD 242.65) |
| MACD | -1.68 (negative) |
Analyst Ratings (ASND)
Wall Street analysts rate ASND "Buy" based on 21 analysts, with a mean price target of USD 307.57 (range USD 261.99–349.56), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 307.57 |
| High Target | USD 349.56 |
| Low Target | USD 261.99 |
| Buy / Hold / Sell | 21 / 0 / 0 |
Earnings (ASND)
| EPS Estimate | USD 0.94 |
|---|---|
| Revenue Estimate | $367.25M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.9 vs est 0.77 ▲ beat |
| 2026-03-31 | USD 0.27 vs est -0.08 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (ASND)
| Total Revenue | $1.05B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +114.70% |
| Gross Margin | +91.30% |
| Operating Margin | +64.98% |
| Profit Margin | +70.84% |
| ROE | +118.78% |
| Debt / Equity | 0.31 |
| Current Ratio | 2.99 |
| Total Cash | $812.26M |
| Total Debt | $450.07M |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (ASND)
Nexqual rates Ascendis Pharma A/S's overall financial health "Strong" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Strong — Revenue +98% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 91%, operating 65% (last 12 months) |
| Balance Sheet | Strong — EUR 812M cash vs EUR 450M debt, net cash position |
| Cash Flow | Solid — Operating cash flow EUR 350M (TTM) |
| Efficiency | Strong — ROE 119%, ROA 9.6% |
Ownership (ASND)
| Insider Ownership | +0.77% |
|---|---|
| Institutional Ownership | +102.99% |
| Shares Outstanding | 65.80M |
| Float | 65.64M |
| Short % of Float | +6.27% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (ASND)
Ascendis Pharma A/S is led by Jan Moller Mikkelsen, President, CEO, Member of Executive Board & Executive Director, per Nexqual as of October 23, 2026 at 10:11 UTC.
| President, CEO, Member of Executive Board & Executive Director | Jan Moller Mikkelsen |
|---|---|
| CFO, Executive VP & Member of Executive Board | Scott T. Smith |
| Vice President of Investor Relations | Chad Fugure |
| Executive Vice President of Product Supply & Quality | Flemming Steen Jensen |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EXEL | Exelixis, Inc. | USD 65.31 | ▲ 1.13% |
| HALO | Halozyme Therapeutics, Inc. | USD 124.54 | ▼ 0.23% |
| JAZZ | Jazz Pharmaceuticals plc | USD 214.65 | ▲ 1.26% |
| BBIO | BridgeBio Pharma, Inc. | USD 68.12 | ▲ 0.56% |
| INSM | Insmed Incorporated | USD 95.06 | ▲ 1.08% |
| SMMT | Summit Therapeutics Inc. | USD 15.55 | ▼ 1.77% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt